Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diazoxide in Obesity and Insulin Resistance with MASLD
NCT07403604Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Jul 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Placebo first, then Diazoxide with Placebo / Placebo (2 arms). Primary endpoint: Hepatic de novo lipogenesis at Day 16. Started Jul 2026; status: recruiting.
02
Drugs
diazoxide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07403604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403604.